Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-D6)

Anti-SARS-CoV-2 Nucleocapsid (N) (Clone NP1-D6)

Product No.: LT7070

- -
- -
Product No.LT7070
Clone
NP1-D6
Target
SARS-CoV-2 Nucleocapsid (N)
Product Type
Recombinant Monoclonal Antibody
Alternate Names
COV2-NP1-D6, SARS-CoV-2 Nucleocapsid, SARS-CoV-2 Nucleoprotein, Protein N, SARS-CoV N Protein
Isotype
Human IgG1
Applications
ELISA

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
SARS-CoV-2
Virus
Host Species
Mouse
Expression Host
HEK-293 Cells
Immunogen
SARS-CoV-2 Nucleocapsid (N) Protein
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
< 1.0 EU/mg as determined by the LAL method
Purity
≥95% monomer by analytical SEC
Formulation
This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Ships Overnight on Blue Ice
Applications and Recommended Usage?
Quality Tested by Leinco
ELISA
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
Anti-SARS-CoV-2 Nucleocapsid, clone NP1-D6, specifically targets an epitope on the SARS-CoV-2 nucleocapsid protein. Futhermore, it is reported to bind to the oligomerization domain of the N protein.
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is an enveloped, single-stranded, positive-sense RNA virus belonging to the Coronaviridae family1. The SARS-CoV-2 genome encodes four essential proteins: the spike (S), envelope (E), membrane (M), and nucleocapsid (N) proteins2. SARS-CoV-2 shares 79.6% identity with the original SARS-CoV2. The N protein is 46 kDa and consists of two highly conserved structural domains, the N-terminal domain (NTD) and C-terminal domain (CTD), connected by a linker region. The NTD and CTD are involved in a couple of primary functions, including RNA binding and self-oligomerization3,4. This results in binding to and packaging of the viral RNA genome into a helical ribonucleoprotein5. The N protein is involved in other critical steps of the viral life cycle, including transcription, replication, and modulating infected cell signaling pathways6,7. The N protein is a suitable candidate for vaccine development and diagnostic assays8 for several reasons. It is abundantly expressed during infection and is highly conserved, sharing 90% amino acid homology with the SARS-CoV N protein9. Furthermore, antibodies9,10 and memory T cells11,12 targeting the N protein are identified in the sera of convalescent COVID-19 patients, demonstrating it as immunogenic. The N protein also suppresses antiviral RNAi, evading the innate immune system13, suggesting its potential value as a targeted therapeutic.
Antigen Distribution
The nucleocapsid protein is expressed in the internal nucleocapsid of SARS-CoV-2.

Antigen Details

NCBI Gene Bank ID
Research Area
COVID-19
.
Seasonal and Respiratory Infections
.
Viral
.
IVD Raw Material

References & Citations

1. Zhou, P., Yang, X., Wang, X. et al. Nature 579, 270–273. 2020.
2. Wu, F., Zhao, S., Yu, B. et al. Nature 579, 265–269. 2020.
3. Kang S, Yang M, Hong Z, et al. Acta Pharm Sin B. 10.1016/j.apsb.2020.04.009. 2020.
4. Chang CK, Sue SC, Yu TH, et al. J Biomed Sci. 13(1):59-72. 2006.
5. Hsieh PK, Chang SC, Huang CC, et al. J Virol. 79(22):13848-13855. 2005.
6. Surjit M, Lal SK. Infect Genet Evol. 8(4):397-405. 2008.
7. Hurst KR, Ye R, Goebel SJ, Jayaraman P, Masters PS. J Virol. 84(19):10276-10288. 2010.
8. Liu L, Liu W, Zheng Y, et al. Microbes Infect. 22(4-5):206-211. 2020.
9. Guo L., Ren L., Yang S., et al. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2020.
10. To K.K., Tsang O.T., Leung W.S., et al. Lancet Infect. Dis. 2020.
11. Grifoni A., Weiskopf D., Ramirez S.I., et al. Cell. 2020.
12. Ni L, Ye F, Cheng ML, et al. Immunity. 52(6):971-977.e3. 2020.
13. Mu J, Xu J, Zhang L, et al. Sci China Life Sci. 1-4. 2020.
Indirect Elisa Protocol

Certificate of Analysis

Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.